Ocular Therapeutix announced that the first three subjects have been screened and received their first aflibercept injection in the Phase 3 SOL-1 clinical trial of AXPAXLI for the treatment of wet age-related macular degeneration. The Company previously announced FDA agreement on its Special Protocol Assessment Agreement Modification on January 25th.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OCUL:
- PayPal downgraded, United Airlines upgraded: Wall Street’s top analyst calls
- Ocular Therapeutix initiated with a Buy, $15 target at BofA
- Ocular Therapeutix initiated with a Buy at BofA
- Ocular Therapeutix Updates Phase 3 SOL Trial Protocol
- Ocular Therapeutix announces FDA agreement to amend SPA for AXPAXLI